sales@intentmarketresearch.com
+1 463-583-2713
As per Intent Market Research, the Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.2 billion in 2023 and will surpass USD 20.4 billion by 2030; growing at a CAGR of 21.6% during 2024 - 2030.
The Advanced Therapy Medicinal Products (ATMP) CDMO market has become a key area of focus in the biopharmaceutical industry, driven by the increasing demand for gene therapies, cell therapies, and tissue-engineered products. These therapies, which offer highly personalized treatment options, are seen as a revolutionary approach for managing diseases that are difficult to treat through traditional methods, such as genetic disorders, cancers, and neurological diseases. With such innovations, the market for contract development and manufacturing organizations (CDMOs) in the ATMP sector has expanded rapidly as companies require specialized services for the development, production, and commercialization of these complex therapies.
Among the various types of therapies, gene therapy has emerged as the fastest-growing segment within the ATMP market. This is primarily driven by the increasing use of gene editing technologies like CRISPR and advancements in the understanding of genetic disorders. Gene therapies offer potential cures for inherited genetic conditions, cancers, and other chronic diseases by targeting the root cause—faulty genes. As a result, the demand for gene therapy products has surged, leading to increased investments in gene therapy manufacturing capabilities. CDMOs in this space are enhancing their services to meet stringent regulatory requirements and high-quality standards, making gene therapy the most dynamic segment in the ATMP CDMO market.
The rapid development of gene therapies has also spurred demand for specialized manufacturing services that are scalable and adaptable to evolving therapeutic needs. CDMOs are increasingly adopting cutting-edge technologies and innovations in their facilities to meet these demands, ensuring that they can offer end-to-end services from clinical development through to commercialization. This growth is supported by partnerships and acquisitions between biotech firms and CDMOs, aiming to strengthen capabilities in gene therapy development and production.
In the service type category, process development stands as the largest segment in the ATMP CDMO market. The complexity of ATMPs, particularly gene and cell therapies, requires extensive process development capabilities to ensure that the products can be scaled from the laboratory to clinical trials and, eventually, to large-scale commercial production. Process development includes designing and optimizing the methods used to produce therapies, which often involve intricate biological processes and require highly specialized equipment and expertise.
CDMOs offering robust process development services play a crucial role in helping biotech and pharmaceutical companies navigate these complexities. They provide services such as cell line development, vector design, and the scaling of production processes—all of which are critical to the success of ATMPs. As the demand for ATMPs grows, the process development segment continues to receive significant attention and investment, with CDMOs continually expanding their capabilities to meet the rising needs of gene and cell therapy developers.
In terms of end-user industries, the BFSI (Banking, Financial Services, and Insurance) sector is the largest contributor to the growth of the ATMP CDMO market. This is primarily due to the significant financial backing and regulatory support that the BFSI industry provides to the biotechnology sector, particularly for the high-cost, high-risk development of advanced therapies. Financial institutions often provide funding for ATMP developers, while insurers work on integrating coverage for gene and cell therapies, which are expensive but offer potentially life-saving treatments.
The collaboration between the BFSI sector and biotech companies creates a solid foundation for the growth of the ATMP CDMO market. With large financial institutions investing in the research and development of gene therapies, the funding flow continues to support the development of more effective and innovative treatments. Additionally, insurance coverage for these therapies is expanding, which further boosts the demand for ATMP manufacturing services.
In terms of applications, thermal energy storage is the fastest-growing area in the ATMP CDMO market. While thermal energy storage is a sector primarily associated with energy industries, there is an increasing overlap with healthcare applications, especially in managing the temperature of sensitive biologic materials and drug products. As the demand for renewable energy solutions and efficient storage systems rises, thermal energy storage methods are increasingly being applied to store energy generated by sustainable sources like solar power.
The increasing adoption of thermal storage in various energy systems has further driven the demand for ATMPs in energy storage applications, especially in designing storage solutions that maintain ideal temperatures for ATMPs. Companies are focusing on innovative solutions that combine energy storage with pharmaceutical-grade temperature regulation, ensuring that advanced therapies, such as gene and cell treatments, are stored and transported under optimal conditions.
North America is the largest region in the ATMP CDMO market, primarily due to the region's well-established biotech infrastructure, robust regulatory environment, and significant investments in research and development. The United States, in particular, is home to a large number of biotechnology firms, many of which are pioneers in the gene and cell therapy space. The presence of leading pharmaceutical companies, academic research institutions, and regulatory bodies like the FDA has facilitated the rapid development and commercialization of ATMPs in this region.
Additionally, North America is seeing increasing investments from both public and private sectors, including venture capital funding for biotechnology startups and collaborations between large pharmaceutical companies and CDMOs. These investments help accelerate the development and manufacturing of advanced therapies, contributing to the region’s dominance in the global market.
The ATMP CDMO market is highly competitive, with several leading players that provide a range of services, from process development to commercialization of advanced therapies. Lonza Group is one of the key leaders, offering an integrated service platform for cell and gene therapy manufacturing. Other prominent companies in the market include WuXi AppTec, Samsung Biologics, and Boehringer Ingelheim, which have expanded their manufacturing capacities to meet the growing demand for ATMPs.
The market is marked by a high level of collaboration, as biotech companies often partner with CDMOs to leverage their expertise in scaling complex manufacturing processes. Additionally, the continuous advancement in manufacturing technologies, regulatory compliance, and innovations in gene therapy are driving companies to enhance their service offerings and remain competitive in this rapidly growing sector. The competitive landscape is also characterized by strategic acquisitions, such as Catalent’s acquisition of Paragon Bioservices, to strengthen its gene therapy manufacturing capabilities. The ongoing expansion of CDMO services, coupled with the growing demand for personalized therapies, ensures that the market will continue to evolve and expand in the coming years
Report Features |
Description |
Market Size (2023) |
USD 5.2 Billion |
Forecasted Value (2030) |
USD 20.4 Billion |
CAGR (2024 – 2030) |
21.6% |
Base Year for Estimation |
2023 |
Historic Year |
2022 |
Forecast Period |
2024 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Advanced Therapy Medicinal Products (ATMP) CDMO Market By Therapy Type (Gene Therapy, Cell Therapy, Tissue Engineering), By Service Type (Process Development, Manufacturing, Regulatory Services, Analytical Services), By End-User Industry (Pharmaceutical & Biotechnology, Contract Manufacturing Organizations, Research Institutions, Hospitals & Clinics), By Application (Oncology, Cardiovascular Disorders, Genetic Disorders, Orthopedic Disorders, Neurological Disorders) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
Lonza Group, Samsung Biologics, WuXi AppTec, Boehringer Ingelheim, Catalent, Kite Pharma (Gilead Sciences), Novartis (Kymriah), Sartorius Stedim Biotech, Regeneron Pharmaceuticals, VWR International, Cell and Gene Therapy Catapult, WuXi Advanced Therapies, AbbVie, Baxter International, Merck Group |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Advanced Therapy Medicinal Products CDMO Market, by Type of Therapy (Market Size & Forecast: USD Million, 2022 – 2030) |
4.1. Gene Therapy |
4.2. Cell Therapy |
4.3. Tissue Engineering |
4.4. Others |
5. Advanced Therapy Medicinal Products CDMO Market, by Service Type (Market Size & Forecast: USD Million, 2022 – 2030) |
5.1. Process Development |
5.2. Manufacturing |
5.3. Regulatory Services |
5.4. Analytical Services |
5.5. Others |
6. Advanced Therapy Medicinal Products CDMO Market, by End-User Industry (Market Size & Forecast: USD Million, 2022 – 2030) |
6.1. Pharmaceutical & Biotechnology |
6.2. Contract Manufacturing Organizations (CMOs) |
6.3. Research Institutions |
6.4. Hospitals & Clinics |
6.5. Others |
7. Advanced Therapy Medicinal Products CDMO Market, by Application (Market Size & Forecast: USD Million, 2022 – 2030) |
7.1. Oncology |
7.2. Cardiovascular Disorders |
7.3. Genetic Disorders |
7.4. Orthopedic Disorders |
7.5. Neurological Disorders |
7.6. Others |
8. Regional Analysis (Market Size & Forecast: USD Million, 2022 – 2030) |
8.1. Regional Overview |
8.2. North America |
8.2.1. Regional Trends & Growth Drivers |
8.2.2. Barriers & Challenges |
8.2.3. Opportunities |
8.2.4. Factor Impact Analysis |
8.2.5. Technology Trends |
8.2.6. North America Advanced Therapy Medicinal Products CDMO Market, by Type of Therapy |
8.2.7. North America Advanced Therapy Medicinal Products CDMO Market, by Service Type |
8.2.8. North America Advanced Therapy Medicinal Products CDMO Market, by End-User Industry |
8.2.9. North America Advanced Therapy Medicinal Products CDMO Market, by Application |
8.2.10. By Country |
8.2.10.1. US |
8.2.10.1.1. US Advanced Therapy Medicinal Products CDMO Market, by Type of Therapy |
8.2.10.1.2. US Advanced Therapy Medicinal Products CDMO Market, by Service Type |
8.2.10.1.3. US Advanced Therapy Medicinal Products CDMO Market, by End-User Industry |
8.2.10.1.4. US Advanced Therapy Medicinal Products CDMO Market, by Application |
8.2.10.2. Canada |
8.2.10.3. Mexico |
*Similar segmentation will be provided for each region and country |
8.3. Europe |
8.4. Asia-Pacific |
8.5. Latin America |
8.6. Middle East & Africa |
9. Competitive Landscape |
9.1. Overview of the Key Players |
9.2. Competitive Ecosystem |
9.2.1. Level of Fragmentation |
9.2.2. Market Consolidation |
9.2.3. Product Innovation |
9.3. Company Share Analysis |
9.4. Company Benchmarking Matrix |
9.4.1. Strategic Overview |
9.4.2. Product Innovations |
9.5. Start-up Ecosystem |
9.6. Strategic Competitive Insights/ Customer Imperatives |
9.7. ESG Matrix/ Sustainability Matrix |
9.8. Manufacturing Network |
9.8.1. Locations |
9.8.2. Supply Chain and Logistics |
9.8.3. Product Flexibility/Customization |
9.8.4. Digital Transformation and Connectivity |
9.8.5. Environmental and Regulatory Compliance |
9.9. Technology Readiness Level Matrix |
9.10. Technology Maturity Curve |
9.11. Buying Criteria |
10. Company Profiles |
10.1. Lonza Group |
10.1.1. Company Overview |
10.1.2. Company Financials |
10.1.3. Product/Service Portfolio |
10.1.4. Recent Developments |
10.1.5. IMR Analysis |
*Similar information will be provided for other companies |
10.2. Samsung Biologics |
10.3. WuXi AppTec |
10.4. Boehringer Ingelheim |
10.5. Catalent |
10.6. Kite Pharma (Gilead Sciences) |
10.7. Novartis (Kymriah) |
10.8. Sartorius Stedim Biotech |
10.9. Regeneron Pharmaceuticals |
10.10. VWR International |
10.11. Cell and Gene Therapy Catapult |
10.12. WuXi Advanced Therapies |
10.13. AbbVie |
10.14. Baxter International |
10.15. Merck Group |
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Advanced Therapy Medicinal Products CDMO Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Advanced Therapy Medicinal Products CDMO Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the Advanced Therapy Medicinal Products CDMO ecosystem. The primary research objectives included:
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Advanced Therapy Medicinal Products CDMO Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment